Intercept to Present at Upcoming Investor Conference
December 09 2016 - 5:00PM
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical
company focused on the development and commercialization of novel
therapeutics to treat progressive non-viral liver diseases, today
announced management will be participating in following investor
conference:
- BMO Prescriptions for Success Healthcare Conference on December
14, 2016 at 1:00 p.m. Eastern Time
Webcast information for this event will be available on the
Investors page of Intercept's website at
http://ir.interceptpharma.com. Archived webcasts will be available
on Intercept's website for approximately two weeks.
About InterceptIntercept is a biopharmaceutical
company focused on the development and commercialization of novel
therapeutics to treat non-viral, progressive liver diseases,
including primary biliary cholangitis (PBC), nonalcoholic
steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and
biliary atresia. Founded in 2002 in New York, Intercept now has
operations in the United States, Europe and Canada.
For more information about Intercept Pharmaceuticals, please contact:
Intercept Pharmaceuticals:
Mark Vignola
+1-646-747-1000
investors@interceptpharma.com
Media inquiries: media@interceptpharma.com
Investor inquiries: investors@interceptpharma.com
Intercept Pharmaceuticals (NASDAQ:ICPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Intercept Pharmaceuticals (NASDAQ:ICPT)
Historical Stock Chart
From Apr 2023 to Apr 2024